Featured Articles

91. First Clinical Trial Using Stem Cell Therapy To Treat Septic Shock 5/12/2021

     An Ottawa Hospital Research Institute’s Cell Manufacturing Facility successfully conducted a Phase I clinical trial examining the safety and efficacy of allogeneic bone marrow-derived MSCs as a treatment for patients experiencing septic shock. Before initiating clinical Phase II studies, the protocol for generating large quantities of MSCs had to be established to reduce end-product variability, minimize production costs, and to ensure sufficient yield to treat multiple patients. Maximizing the yield of viable cells proved challenging in a limited footprint.

92. Process Development In Gene Therapy: 4 Things To Know 5/12/2021

    Considering everything it takes to scale up gene therapy — the platforms, the media, the surfaces, the vessels, the equipment — developing viral vector production processes comes with many challenges.

93. Improving Scale-Up Efficiency 4/27/2021

    A compilation of research experiences using an industry standard for a variety of adherent cell expansion applications, including viral vector manufacturing, stem cell expansion, and vaccine production.

94. Corning® KBM581: Nutritious, Serum-free Media For CAR-T Cell Expansion 4/26/2021

    When considering an adoptive cell therapy approach, the transfusion of a sufficient number of CAR-T cells with an appropriate phenotype is critical. Corning KBM581 has been shown to be a nutritious, safe, and serum-free medium for other immune cell therapies, such as CIK and NK cells. To discover which medium among several commercialized media (including KBM581) is most appropriate for supporting CAR-T cell growth, the research group from Bioraid Bio generated CAR-T cells and analyzed the expansion folds and phenotype between different media in this application note.

95. Corning® 100 mm Aseptic Transfer Cap For 5L Erlenmeyer Flasks: An Aseptic Solution For Liquid Transfer 4/26/2021

    Closed cell culture systems play a significant role in reducing the risk of contamination during liquid handling. The Corning 100 mm aseptic transfer cap (ATC) offers a closed system solution for transferring liquid aseptically into or out of a Corning 5L Erlenmeyer flask. Here we demonstrate the use of the ATC to seed and expand two suspension cell lines, 5/9 m alpha3-18 and Sf9 cells in the 5L Erlenmeyer flasks.

96. Efficient Expansion Of HEK-293 Suspension Cell Cultures 4/26/2021

    In this study, we assessed the performance of Corning 5L Erlenmeyer flasks with different media fill volumes on the growth of HEK-293F cells, a variant of the HEK-293 cell line

97. Effective Bead-to-Bead Transfer Of Cells In Serum-free Medium Using Polystyrene Corning® Enhanced Attachment Microcarriers 4/26/2021

    To achieve large-scale cell production, a microcarrier culture scale-up strategy is necessary. Several approaches have been developed to achieve the transfer of cells from one microcarrier to another including enzymatic dissociation and bead-to-bead transfer. However, enzymatic dissociation introduces additional process steps (washing, inactivation, and removal of the enzyme) that are not feasible at a large scale. This report describes a method for expansion of anchorage-dependent cells on polystyrene Corning microcarriers with an enhanced attachment surface treatment in serum-free cell culture medium.

98. Efficient Expansion Of Suspension CHO Cells In Corning® PETG Erlenmeyer Flasks 4/26/2021

    The adoption of single-use technologies for biopharmaceutical manufacturing is a rapidly growing trend due to a number of advantages including the reduced risk of contamination, reduced capital costs, and faster time to market. In this study, we assessed the growth of CHO-S cells in Corning 2L, 3L, and 5L PETG flasks with different fill volumes using a typical batch culture protocol. Our results demonstrate efficient expansion and high viability of CHO-S cells in all three flask sizes during 6 days in culture.

99. Expansion Of Vero Cells On Corning® Enhanced Attachment Microcarriers And Demonstration Of Scalability In A Benchtop Bioreactor 4/26/2021

    To address the need for increased cell yields, Corning has commercialized a panel of sterile, ready-to-use microcarriers for the culture of anchorage-dependent cell lines. Here we report on the expansion and scale-up of Vero cells on Corning enhanced attachment microcarriers for vaccine applications. Vero cells are an ideal candidate for microcarrier culture because they are anchorage-dependent and are required in large numbers for cell line-based vaccine production.